Alector, Inc. (NASDAQ: ALEC) is a Healthcare company (Biotechnology) with a market capitalization of $381M. The Maz Rating grades it against the other companies in its sector.
Alector, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.56, Alector, Inc. trades at 7.3x trailing earnings, 2.2x sales and 2.4x book value, with an EV/EBITDA of 7.1. Over the last twelve months it generated about $175M of revenue and $52M of net income. It runs an operating margin of 20.2% and a net margin of 23.9%. It shows return on equity of 112.2%, return on invested capital of 24.8% and a free cash flow yield of -39.4%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 4.10. Over the past 52 weeks the share price ranged from $1.09 to $2.84, with a beta of 0.61.
Alector, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 9 Buy, 3 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.